ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Stock Price Pass Below Fifty Day Moving Average of $57.70

Shares of ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) passed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $57.70 and traded as low as $56.26. ProShares Ultra Nasdaq Biotechnology shares last traded at $58.09, with a volume of 230,404 shares traded.

ProShares Ultra Nasdaq Biotechnology Stock Performance

The business’s 50-day simple moving average is $57.70 and its 200 day simple moving average is $52.14.

ProShares Ultra Nasdaq Biotechnology Announces Dividend

The business also recently declared a dividend, which was paid on Wednesday, March 27th. Shareholders of record on Thursday, March 21st were given a dividend of $0.0403 per share. The ex-dividend date of this dividend was Wednesday, March 20th.

Institutional Trading of ProShares Ultra Nasdaq Biotechnology

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. UBS Group AG grew its stake in shares of ProShares Ultra Nasdaq Biotechnology by 213.6% in the 3rd quarter. UBS Group AG now owns 1,151 shares of the exchange traded fund’s stock worth $55,000 after purchasing an additional 784 shares during the last quarter. JPMorgan Chase & Co. acquired a new position in shares of ProShares Ultra Nasdaq Biotechnology in the 4th quarter worth approximately $115,000. Simplex Trading LLC grew its stake in shares of ProShares Ultra Nasdaq Biotechnology by 5,408.9% in the 4th quarter. Simplex Trading LLC now owns 2,479 shares of the exchange traded fund’s stock worth $141,000 after purchasing an additional 2,434 shares during the last quarter. Vontobel Holding Ltd. increased its position in shares of ProShares Ultra Nasdaq Biotechnology by 11.6% in the first quarter. Vontobel Holding Ltd. now owns 3,321 shares of the exchange traded fund’s stock worth $206,000 after acquiring an additional 344 shares in the last quarter. Finally, Clarity Capital Partners LLC purchased a new position in shares of ProShares Ultra Nasdaq Biotechnology in the fourth quarter worth approximately $201,000.

About ProShares Ultra Nasdaq Biotechnology

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.